SWAMY, Ganesha, Julie BIENERTOVÁ VAŠKŮ, Petr BIENERT, Ota HLINOMAZ a Anna VAŠKŮ. Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease? In New Frontiers in Basic Cardiovascular Research. Hungary: INSERM, France, 2006, s. 82-82.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Atrial Natriuretic Peptide: IS ANP associated with restenosis after Coronary Artery Disease?
Název česky Je variabilita v genu pro atriální natriuretický peptid asociována s výskytem restenózy po PCI?
Autoři SWAMY, Ganesha (826 Velká Británie a Severní Irsko), Julie BIENERTOVÁ VAŠKŮ (203 Česká republika, garant), Petr BIENERT (203 Česká republika), Ota HLINOMAZ (203 Česká republika) a Anna VAŠKŮ (203 Česká republika).
Vydání Hungary, New Frontiers in Basic Cardiovascular Research, od s. 82-82, 1 s. 2006.
Nakladatel INSERM, France
Další údaje
Originální jazyk angličtina
Typ výsledku Stať ve sborníku
Obor Genetika a molekulární biologie
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
Kód RIV RIV/00216224:14110/06:00017441
Organizační jednotka Lékařská fakulta
Klíčová slova anglicky Atrial natriuretic peptide; restenosis; PCI
Štítky Atrial natriuretic peptide, PCI, restenosis
Změnil Změnila: prof. MUDr. Julie Dobrovolná, Ph.D., učo 4805. Změněno: 2. 11. 2006 15:10.
Anotace
Background: ANP has shown over recent studies to play an increasingly pivotal role in the regulation of coronary blood flow and atherosclerosis. The gene polymorphism of interest, transition T2238C (ScaI) in the ANP precursor gene, leads to the abolishment of the regular stop codon and instead translation of an additional two arginines. The purpose of the study is to identify the possible influence of ANP ScaI polymorphism on restenotic phenotypes in coronary artery disease (CAD) patients. Method: This study was performed on 96 consecutive caucasians (24 women and 72 men) with clinically significant coronary artery disease confirmed by means of quantitave coronary angiography with minimum one coronary artery with more than 50% lumen stenosis, and all with bare metal stenting in coronary arteries < 3mm. Results: No differences were found in relation to patients with or without restenosis and the genotype distributions as well as allelic frequencies of examined ANP ScaI polymorphism (p = 0.28). However, there is a borderline significant association of ANP genotype distribution with CAD risk factors, such as hypertension and hyperlipidemia (p = 0.05). According to our findings, the allelic frequencies of the ANP ScaI polymorphism in the Czech CAD population do statistically significantly differ from those described in Polish CAD patients (p = 0.01). Conclusion: The ANP ScaI gene polymorphism, based on our data, is not a genetic marker for restenosis after stenting in CAD patients, but the study does suggest that ANP genotypes, specifically A2A2 variants, may be conducive to hypertension. This may be explained by impaired natriuresis in the kidney, perhaps due to reduced affinity or impaired binding of ANP to its receptor, thus leading to sodium retention and increased extracellular volume. Continued research into ANP and its pathophysiological role we believe is imperative to further elucidate how ANP is associated to hypertension.
Anotace česky
Polymorfismus ScaI v genu pro atriální natriuretický peptid se nezdá být velkým faktorem pro rozvoj restenózy po PCI.
Návaznosti
MSM 141100002, záměrNázev: Molekulární patofyziologie multigenních chorob
Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Molekulární patofyziologie multigenních chorob
VytisknoutZobrazeno: 4. 5. 2024 18:20